Cellebrite price target lowered to $24 from $25 at BofA

BofA lowered the firm’s price target on Cellebrite (CLBT) to $24 from $25 and keeps a Buy rating on the shares. Q2 results and second half guidance were below Street expectations on lasting DOGE efficiency impacts and budget pauses, but “the good news is that it is only a matter of timing,” says the analyst, who believes the company should obtain FedRAMP High ATO status by the first half of 2026, further supporting cloud growth in Federal.